289 related articles for article (PubMed ID: 16365174)
1. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
Richardson P; Anderson K
J Clin Oncol; 2006 Jan; 24(3):334-6. PubMed ID: 16365174
[No Abstract] [Full Text] [Related]
2. [New treatment strategies for multiple myeloma].
Ozaki S
Rinsho Ketsueki; 2009 Oct; 50(10):1506-17. PubMed ID: 19915360
[No Abstract] [Full Text] [Related]
3. Controversies regarding the use of dexamethasone in patients with multiple myeloma.
Rajkumar SV
Clin Adv Hematol Oncol; 2008 Feb; 6(2):103, 141. PubMed ID: 18347560
[No Abstract] [Full Text] [Related]
4. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
5. The emperor's new clothes or the current practice of clinical trials for multiple myeloma in the USA.
Ballester O
Cancer Invest; 2008 Jun; 26(5):445-7. PubMed ID: 18568765
[TBL] [Abstract][Full Text] [Related]
6. Refractory multiple myeloma treated with homoharringtonine: report of two cases.
Yang X; Yang C; Shao K; Ye X; Meng H; Zhou Y; Qian W
Ann Hematol; 2007 Dec; 86(12):919-21. PubMed ID: 17641891
[No Abstract] [Full Text] [Related]
7. Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience.
Caravita T; Siniscalchi A; Tendas A; Cupelli L; Ales M; Perrotti A; Niscola P; de Fabritiis P
Ann Hematol; 2011 Jan; 90(1):115-6. PubMed ID: 20422414
[No Abstract] [Full Text] [Related]
8. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.
Hassoun H; Reich L; Klimek VM; Dhodapkar M; Cohen A; Kewalramani T; Zimman R; Drake L; Riedel ER; Hedvat CV; Teruya-Feldstein J; Filippa DA; Fleisher M; Nimer SD; Comenzo RL
Br J Haematol; 2006 Jan; 132(2):155-61. PubMed ID: 16398649
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.
Wang M; Weber DM; Delasalle K; Alexanian R
Am J Hematol; 2005 Jul; 79(3):194-7. PubMed ID: 15981221
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide plus dexamethasone in multiple myeloma.
Das M
Lancet Oncol; 2018 Jan; 19(1):e12. PubMed ID: 29175148
[No Abstract] [Full Text] [Related]
12. Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma. Finnish Leukaemia Group.
Palva IP; Ahrenberg P; Ala Harja K; Almqvist A; Elonen E; Hallman H; Hänninen A; Ilvonen M; Isomaa B; Jouppila J
Eur J Haematol; 1990 Feb; 44(2):121-4. PubMed ID: 2180741
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide and dexamethasone in patients with multiple myeloma not undergoing upfront autologous stem cell transplantation.
Blade J
Haematologica; 2005 Dec; 90(12):1589. PubMed ID: 16330426
[No Abstract] [Full Text] [Related]
14. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.
Rifkin RM; Gregory SA; Mohrbacher A; Hussein MA
Cancer; 2006 Feb; 106(4):848-58. PubMed ID: 16404741
[TBL] [Abstract][Full Text] [Related]
15. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients.
Goldschmidt H; Sonneveld P; Cremer FW; van der Holt B; Westveer P; Breitkreutz I; Benner A; Glasmacher A; Schmidt-Wolf IG; Martin H; Hoelzer D; Ho AD; Lokhorst HM; ;
Ann Hematol; 2003 Oct; 82(10):654-9. PubMed ID: 12845480
[No Abstract] [Full Text] [Related]
16. Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen.
Kelley TW; Baz R; Hussein M; Karafa M; Cook JR
Hum Pathol; 2009 Mar; 40(3):405-12. PubMed ID: 19070887
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
Ai Zheng; 2007 Dec; 26(12):1369-72. PubMed ID: 18076804
[TBL] [Abstract][Full Text] [Related]
18. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M
J Clin Oncol; 2009 Oct; 27(30):5001-7. PubMed ID: 19720903
[TBL] [Abstract][Full Text] [Related]
19. Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma?
Jimenez-Zepeda VH; Domínguez-Martínez VJ
Eur J Haematol; 2006 Sep; 77(3):239-44. PubMed ID: 16856924
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide and dexamethasone: therapy for multiple myeloma.
Kumar S; Rajkumar SV
Expert Rev Anticancer Ther; 2005 Oct; 5(5):759-66. PubMed ID: 16221046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
